Skip to main content

Table 2 Summary of patient demography and medication, with log-transformed power values of the LF, HF, and TP bands

From: The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine

 All subjects (n = 91)
Age (years)50.30 ± 15.25
Sex (male/female)39/52
Duration of illness (years)19.28 ± 13.35
Smoking (smoker/non-smoker)6/85
BMI (kg/m2)24.01 ± 4.66
CPZeqa (mg/day)491.21 ± 247.05
BPDeqb (mg/day)0.78 ± 1.79
DZPeqc (mg/day)7.62 ± 13.41
PANSS total score72.16 ± 16.00
lnLF (ms2)4.32 ± 1.12
lnHF (ms2)3.81 ± 1.15
lnTotal Power (ms2)4.93 ± 0.99
  1. Data are presented as the mean ± standard deviation
  2. BMI Body mass index, PANSS Positive and Negative Syndrome Scale, ln natural log-transformed, HF High frequency, LF Low frequency, TP Total power
  3. a The daily dosages of antipsychotic drugs were converted to approximate chlorpromazine equivalents
  4. b The daily dosages of anticholinergic antiparkinsonian drugs were converted to approximate biperiden equivalents
  5. c The daily dosages of benzodiazepine were converted to approximate diazepam equivalents